Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion.
Citrome
Leslie
L
New York University School of Medicine, New York City, NY, USA. citrome@nki.rfmh.org
D000328:Adult; D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D018340:Receptors, Adrenergic, alpha-1 / Q000187:drug effects / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology
D014150:Antipsychotic Agents; D007555:Isoxazoles; D010880:Piperidines; D018340:Receptors, Adrenergic, alpha-1; D019389:Cytochrome P-450 CYP2D6; C081732:iloperidone